Further studies are required to understand how ASCL2 regulates IFN-γ and IFN-α responses within the tumor microenvironment, which might prevent the immune evasion and improve the effect of immunotherapies in MSS CRC patients. The gene discussed is IFNG; the disease is neoplasm.